Policy & Regulation
Ipsen reports positive Phase III results for Dysport in episodic and chronic migraine
9 July 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) on Thursday reported positive topline Phase III results from its BEOND migraine programme, with Dysport (abobotuli...
Ionis and AstraZeneca's eplontersen Phase 3 ATTR-CM trial misses primary endpoint, subgroup analysis shows nominal benefit
9 July 2026 - Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) and its partner AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) reported on Thursday that the Phase 3 CARDIO-TTRansform trial...
Altruist Biologics' Hangzhou ADC facility approved for segmented production
9 July 2026 - Contract development and manufacturing organisation (CDMO) Altruist Biologics, a subsidiary of Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801), announced on Wednesd...
Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma
9 July 2026 - Northwest Biotherapeutics (OTCQB:NWBO)(NWBio), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced on Wednesday that the company�...
Lynk Pharmaceuticals reports first patient dosed in Phase II clinical trial for vitiligo treatment
9 July 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced on Wednesday that the first patient has been succ...
HanchorBio plans combination research with late-stage cancer drug resistance specialist InxMed
9 July 2026 - Taiwan-listed clinical-stage biotech HanchorBio Inc (TWSE:7827) announced on Wednesday that it is looking to broaden the development path for HCB101, its lead oncology asset, through a n...